Quick Answer
Larimar Therapeutics, Inc. reported R&D Expense of $154.22 million for fiscal year 2025.
Larimar Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $154.22M | +110.5% |
| 2024 | $73.28M | +164.8% |
| 2023 | $27.67M | +14.1% |
| 2022 | $24.25M | -36.8% |
| 2021 | $38.40M | +22.3% |
| 2020 | $31.41M | +51.1% |
| 2019 | $20.79M | -56.6% |
| 2018 | $47.93M | +17.4% |
| 2017 | $40.84M | +2.3% |
| 2016 | $39.94M | -26.9% |
| 2015 | $54.62M | +99.4% |
| 2014 | $27.39M | +186.5% |
| 2013 | $9.56M | -17.2% |
| 2012 | $11.54M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.93M | +222.8% | +92.3% |
| June 30, 2025 | $23.37M | +18.7% | -12.0% |
| March 31, 2025 | $26.55M | +105.2% | +90.8% |
| September 30, 2024 | $13.92M | +111.4% | -29.3% |
| June 30, 2024 | $19.68M | +235.0% | +52.1% |
| March 31, 2024 | $12.94M | +183.6% | +96.5% |
| September 30, 2023 | $6.58M | +18.0% | +12.1% |
| June 30, 2023 | $5.88M | +4.1% | +28.8% |
- Larimar Therapeutics, Inc. showed an increase of +110.5% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Larimar Therapeutics, Inc.’s r&d expense has grown by 1236.0% (from $11.54 million to $154.22 million).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: